Dai Ichi Life Insurance Company Ltd grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,162 shares of the medical instruments supplier’s stock after buying an additional 655 shares during the quarter. Dai Ichi Life Insurance Company Ltd’s holdings in Becton, Dickinson and were worth $3,934,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Almanack Investment Partners LLC. purchased a new stake in Becton, Dickinson and during the first quarter worth approximately $105,000. Parkside Financial Bank & Trust grew its stake in Becton, Dickinson and by 1.4% during the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the period. QCI Asset Management Inc. NY grew its stake in Becton, Dickinson and by 9.2% during the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 60 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in Becton, Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after buying an additional 240 shares during the period. Finally, Financial Architects Inc grew its stake in Becton, Dickinson and by 8.0% during the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after buying an additional 54 shares during the period. Institutional investors own 87.12% of the company’s stock.

Several research firms have issued reports on BDX. Wells Fargo & Company began coverage on shares of Becton, Dickinson and in a research note on Friday, September 22nd. They set an “outperform” rating and a $225.00 price objective for the company. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Cowen and Company reiterated a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a research note on Monday, August 14th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Five investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $200.93.

COPYRIGHT VIOLATION NOTICE: “Dai Ichi Life Insurance Company Ltd Grows Holdings in Becton, Dickinson and Company (BDX)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/09/dai-ichi-life-insurance-company-ltd-grows-holdings-in-becton-dickinson-and-company-bdx.html.

In other news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the completion of the transaction, the insider now directly owns 14,038 shares in the company, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. In the last three months, insiders sold 75,904 shares of company stock worth $15,242,688. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company (NYSE:BDX) opened at 198.08 on Monday. The stock has a 50 day moving average of $197.22 and a 200 day moving average of $192.46. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The stock has a market capitalization of $45.08 billion, a P/E ratio of 57.36 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. During the same quarter last year, the firm posted $2.35 earnings per share. The company’s quarterly revenue was down 5.1% compared to the same quarter last year. On average, equities research analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were given a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.47%. The ex-dividend date was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is 83.43%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.